Verrica Pharmaceuticals Inc. (VRCA)
Summary
Verrica Pharmaceuticals Q1 Earnings Call Highlights
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1 per share a year ago.
Verrica Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 518,181 | $4.15M | $3.12M | -$1.03M | -24.87% |
| DP Drew Phillips Fortitude Family Office LLC | 127 | $1,055.27 | $717.55 | -$337.72 | -32% |
 Darren Tapley New England Capital Financial Advisors LLC | 200 | $862 | $1,114.08 | $252.08 | 29.24% |
Verrica Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KD Kemp Dolliver Brookline Capital | - | - | - | - | - |
Verrica Pharmaceuticals Inc. (VRCA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Verrica Pharmaceuticals Inc. ever had a stock split?
Verrica Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jayson Rieger CEO | NASDAQ (NMS) Exchange | 92511W207 CUSIP |
| US Country | 76 Employees | - Last Dividend | 25 Jul 2025 Last Split | 15 Jun 2018 IPO Date |
Overview
Verrica Pharmaceuticals Inc. is an innovative clinical-stage dermatology therapeutics company based in West Chester, Pennsylvania, focusing on the development of novel medications for various skin diseases. Founded in 2013, the company actively works on creating effective therapeutic solutions, emphasizing diseases that currently lack satisfactory treatments. A significant part of Verrica's mission involves targeting challenging dermatological conditions through rigorous clinical trials and strategic collaborations. To this end, it has entered into meaningful partnerships, including with Torii Pharmaceutical Co., Ltd., for the advancement and commercialization of products in Japan, and with Lytix Biopharma AS for the development of dermatological oncology indications. These collaborative efforts are geared toward leveraging Verrica's innovative product pipeline to meet the unmet needs of patients with dermatological conditions globally.
Products and Services
- YCANTH (VP-102)
This leading product candidate is currently in a phase III clinical trial targeting the treatment of common warts. Its application has also been extended to external genital warts, for which it has completed phase II clinical trials. YCANTH showcases Verrica's dedication to addressing prevalent yet often overlooked dermatological issues with innovative, clinically tested solutions. Additionally, it is approved for treating molluscum contagiosum, highlighting its versatility and potential in dermatology.
- VP-315
VP-315 is an oncolytic peptide-based injectable therapy in phase II clinical trial aimed at treating dermatology oncological conditions such as basal cell carcinoma. This product highlights Verrica's venture into dermatological oncology, demonstrating the company's broader commitment to combatting skin-related cancers through pioneering therapeutic approaches. The development and commercialization rights for VP-315 have been licensed in collaboration with Lytix Biopharma AS, focusing on significant dermatological oncology indications including non-metastatic melanoma and non-metastatic merkel cell carcinoma.
- VP-103
VP-103, a cantharidin-based product candidate, is another testament to Verrica's innovative approach to dermatology. It is currently undergoing phase II clinical trial for the treatment of plantar warts. This development underscores the company's dedication to expanding its product pipeline to include treatments for a broader range of dermatological conditions, providing hope for patients suffering from these often painful and persistent skin issues.
